• 1
    Australian Institute of Health and Welfare. Cancer in Australia: An Overview 2010. Canberra: Australian Government, 2010: Cancer series number 60 AIHW cat no CAN 56. Available at: Accessed 19 September 2012
  • 2
    Australian Institute for Health and Welfare (AIHW) and Australasian Association of Cancer Registries (AACR). Cancer in Australia: An Overview, 2010. Canberra: AIHW, 2008: Cancer Series no. 60. Cat. No. CAN 56. Available at: Accessed 19 September 2012
  • 3
    Glass P, Tracey E, Smetanin P, Kobak P, Pavilichev A, Bis J. Lives at Risk for Cancer in New South Wales 2007–2036: A Health Economics Study of Cancer in New South Wales. Eveleigh: Cancer Institute NSW, 2008
  • 4
    Wilt TJ, Brawer MK, Jomes KM et al. Radical prostatectomy versus observation for localized prostate cancer. New England Journal of Medicine 2012; 367: 20313
  • 5
    Arvold ND, Chen MH, Moul JW et al. Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease. J Urol 2011; 186: 916
  • 6
    Coory MD, Baade PD. Urban–rural differences in prostate cancer mortality, radical prostatectomy and prostate-specific antigen testing in Australia. Med J Aust 2005; 182: 1125
  • 7
    English D, Farrugia H, Thursfield V, Chang P, Giles GG. Cancer Survival, Victoria 2007. Melbourne: The Cancer Council Victoria, 2007
  • 8
    Hayen A, Smith DP, Patel MI, O'Connell DL. Patterns of surgical care for prostate cancer in NSW, 1993–2002: rural/urban and socio-economic variation. Aust NZ J Public Health 2008; 32: 41720
  • 9
    Karakiewicz PI, Eastham JA, Graefen M et al. Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5831 patients. Urology 2005; 66: 124550
  • 10
    Eastham JA, Kattan MW, Riedel E et al. Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J Urol 2003; 170: 22925
  • 11
    Klein EA, Bianco FJ, Serio AM et al. Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. J Urol 2008; 179: 22126
  • 12
    Leibel SA, Hanks GE, Kramer S. Patterns of care outcome studies: results of the national practice in adenocarcinoma of the prostate. Radiat Oncol Biol 1984; 10: 4019
  • 13
    Spencer BA, Miller DC, Litwin MS et al. Variations in quality of care for men with early-stage prostate cancer. J Clin Oncol 2008; 26: 373542
  • 14
    Cancer Epidemiology Centre. Canstat: Prostate Cancer. No 30. Anti-Carlton: Cancer Council of Victoria, 2000
  • 15
    Victorian Consolidated Legislation. Cancer Act 1958 (Principlal Act No. 6213) As Amended by Legislation (Cancer [Cancer Reporting] Act 1980 No. 9494). Melbourne: Government of Victoria, 1980
  • 16
    Tu JV, Willison DJ, Silver FL et al. Impracticability of informed consent in the registry of the Canadian Stroke Network. N Engl J Med 2004; 350: 141421
  • 17
    Australian Institute of Health and Welfare. METeOR Metadata Online Registry [Web Page]. Available at: Accessed 6 March 2012
  • 18
    Commission on Cancer. Facility Oncology Registry Standards (FORDS). Chicago: American College of Surgeons, 2002
  • 19
    Eyenet Sweden. Handbook for Establishing Quality Registries. Karlskrona: Eyenet Sweden, 2005
  • 20
    Australian Cancer Network Working Party on Management of Localised Prostate Cancer. Clinical Practice Guidelines: Evidence-Based Information and Recommendations for the Management of Localised Prostate Cancer. Canberra: Commonwealth of Australia, 2002
  • 21
    American Urology Association. Prostate Cancer: Guideline for the Management of Clinically Localized Prostate Cancer: 2007 update. Available at: Accessed 19 September 2012
  • 22
    National Collaborating Centre for Cancer. Prostate Cancer: Diagnosis and Treatment. NICE Clinical Guideline 58. London: National Institute for Clinical Excellence (NICE), 2008
  • 23
    Spencer B, Steinberg M, Malin J et al. Quality-of-care indicators for early-stage prostate cancer. J Clin Oncol 2003; 21: 192836
  • 24
    Evans S, Lowinger J, Sprivulis P, Hagger V, Copnell B, Cameron P. Prioritising quality indicator development across the healthcare system: identifying what to measure. Intern Med J 2009; 39: 64854
  • 25
    National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Prostate Cancer. Available at: Accessed 19 September 2012
  • 26
    Cooperberg MR, Pasta DJ, Elkin EP et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005; 173: 193842
  • 27
    Lughezzani G, Budaus L, Isbarn H et al. Head-to-head comparison of the three most commonly used preoperative models for prediction of biochemical recurrence after radical prostatectomy. Eur Urol 2010; 57: 5628
  • 28
    Ware JE, Kosinski M, Turner-Bowker DM, Gandek B. User's Manual for the SF-12v2 Health Survey with A Supplement Documenting SF-12 Health Survey. Lincoln: Quality Metrics Incorporated, 2009
  • 29
    Brazier JE, Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care 2004; 42: 8519
  • 30
    Litwin MS, McGuigan KA. Accuracy of recall in health-related quality-of-life assessment among men treated for prostate cancer. J Clin Oncol 1999; 17: 28828
  • 31
    van Andel G, Bottomley A, Fossa S et al. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer 2008; 44: 241824
  • 32
    Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 1997; 50: 9208
  • 33
    Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000; 56: 899905
  • 34
    Litwin M, Hays R, Fink A, Ganz P, Leake B, Brook R. The UCLA Prostate Cancer Index: development, reliablility, and validity of a health-related quality of life measure. Med Care 1998; 36: 100212
  • 35
    Jorgensen CK, Karlsmose B. Validation of automated forms processing. A comparison of teleform with manual data entry. Comput Biol Med 1998; 28: 65967
  • 36
    Partin AW, Yoo J, Carter HB et al. The use of prostate specific antigen, clinical stage and gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150: 1104
  • 37
    Stone NN, Stone MM, Rosenstein BS, Unger P, Stock RG. Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy. J Urol 2011; 185: 495500
  • 38
    Reece AC, Cooperberg MR, Carroll PR. Minimal impact of clinical stage on prostate cancer prognosis among contemporary patients with clinically localized disease. J Urol 2010; 184: 1149
  • 39
    Reece AC, Sadetsky N, Carroll PR, Cooperberg MR. Inaccuracies in assignment of clinical stage for localized prostate cancer. Cancer 2011; 117: 2839
  • 40
    Miller DC, Spencer B, Ritchey J et al. Treatment choice and quality of care for men with localized prostate cancer. Med Care 2007; 45: 4019
  • 41
    Australian Commission on Safety and Quality in Health Care. Operating Principles and Technical Standards for Australian Clinical Quality Registries. November 2008. Available at:$File/02_Architecture%20and%20Technical%20Standards%20for%20Australian%20Clinical%20Quality%20Registries%20(full%20doc)%20(PDF%20863%20KB).PDF. Accessed 19 September 2012
  • 42
    Van Hemelrijck M, Wigertz A, Sandin F et al. Cohort Profile: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0. Int J Epidemiol 2012 [Epub ahead of print]. doi: 10.1093/ije/dys06843
  • 43
    Porten SP, Cooperberg MR, Konety BR, Carroll PR. The example of CaPSURE: lessons learned from a national disease registry. World J Urol 2011; 29: 26571